skip to Main Content

In vivo regeneration of interspecies chimeric kidneys using a nephron progenitor cell replacement system.


Maximus Peto’s Commentary

I wonder whether this interesting report of kidney regeneration might be relevant for repairing or rejuvenating dysfunctional kidneys in aging humans.


In vivo regeneration of interspecies chimeric kidneys using a nephron progenitor cell replacement system.
Sci Rep. 2019 May 6;9(1):6965.
Toshinari Fujimoto, Shuichiro Yamanaka, Susumu Tajiri, Tsuyoshi Takamura, Yatsumu Saito, Kei Matsumoto, Kentaro Takase, Shohei Fukunaga, Hirotaka James Okano, Takashi Yokoo
DOI: 10.1038/s41598-019-43482-2
PubMed publication date (edat): 5/8/2019

Abstract

…By transplanting exogeneous nephron progenitor cells (NPCs) into the metanephric mesenchyme of a xenogeneic foetus, we aimed to regenerate neo-kidneys that originate from transplanted NPCs. Previously, we generated a transgenic mouse model enabling drug-induced ablation of NPCs (the Six2-iDTR mouse). We demonstrated that eliminating existing native host NPCs allowed their 100% replacement with donor mouse or rat NPCs, which could generate neo-nephrons on a culture dish. To apply this method to humans in the future, we examined the possibility of the in vivo regeneration of nephrons between different species via NPC replacement. We injected NPCs-containing rat renal progenitor cells and diphtheria toxin below the renal capsule of E13.5 metanephroi (MNs) of Six2-iDTR mice; the injected MNs were then transplanted into recipient rats treated with immunosuppressants. Consequently, we successfully regenerated rat/mouse chimeric kidneys in recipient rats receiving the optimal immunosuppressive therapy. We revealed a functional connection between the neo-glomeruli and host vessels and proper neo-glomeruli filtration. In conclusion, we successfully regenerated interspecies kidneys in vivo that acquired a vascular system. This novel strategy may represent an effective method for human kidney regeneration.

PMID: 31061458
Free Full-Text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6502858/

Maximus Peto

Max Peto is a longevity researcher and founder of Long Life Labs. A biochemist by training, he studies the biochemistry of aging and longevity and has worked with research organizations such as SENS Research Foundation, Methuselah Foundation, BioAge Labs, Life Extension Foundation, and Ichor Therapeutics. His work at Long Life Labs is focused on empowering people to understand and manage the most critical factors for better health and longer life.

Free report on high blood pressure

The American Heart Association estimates more than 100 million Americans have high blood pressure, also known as “hypertension”. Learn more about the cause of high blood pressure and how you can reverse it in our free report.

Coming soon. We’ll send you the report as soon as it’s published.

*We do not share your email address with anyone.

Free longevity biomarker report

Biomarker levels predict the risk of early death—and we can change them! Learn about some important longevity biomarkers in our free report.

Coming soon. We’ll send you the report as soon as it’s published.

*We do not share your email address with anyone.

Free diabetes report

An estimated 50% of American adults have either prediabetes or type 2 diabetes. Learn more about the cause of type 2 diabetes, prediabetes, insulin resistance, and how to reverse them in our free report.

Coming soon. We’ll send you the report as soon as it’s published.

*We do not share your email address with anyone.

Back To Top